<DOC>
	<DOC>NCT02648386</DOC>
	<brief_summary>Erectile dysfunction (ED) is one of the commonest complications in men after rectal cancer treatment. The purpose of this study is to assess the safety and efficacy of autologous bone marrow mononuclear cells (BMMCs) or allogeneic human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) combined with NeuroRegen scaffold transplantation in men with erectile dysfunction after rectal cancer treatment.</brief_summary>
	<brief_title>Stem Cell Therapy Combined With NeuroRegen Scaffoldâ„¢ in Patients With Erectile Dysfunction After Rectal Cancer Surgery</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>1. Diagnosed with local rectal cancer, which is within 12cm from anus. 2. Male, 2065 years old. 3. IIEF5 score&gt; 21. 4. No obvious abnormal in external genitalia, testis, epididymis and spermatic cord. 5. Have a consistent partner who is willing to engage in sexual activity more than twice per month during the study. 6. Signed informed consent. 7. Recently take no drugs affecting sexual function (such as androgen replacement drugs, PDE5i and Chinese patent medicine, etc.). 1. Suffering hypertension or diabetes. 2. In the investigators judgment, with clinical significance of penis abnormalities, or has received penile prosthesis implantation surgery. 3. Patient's partner is trying to conceive during the trial period. 4. Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study. 5. Geographically inaccessible for followup visits required by protocol or want to other treatment.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>